Novartis AG (ADR)
General ticker "NVS" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $260.6B (TTM average)
Novartis AG (ADR) follows the US Stock Market performance with the rate: 40.3%.
Estimated limits based on current volatility of 1.2%: low 149.97$, high 153.67$
Factors to consider:
- Earnings expected soon, date: 2026-07-21 bmo
- Company pays dividends (annually): last record date 2026-03-11, amount 4.74$ (Y3.08%)
- Total employees count: 69068 as of 2000
- Price in estimated range
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [113.24$, 154.59$]
- 2026-12-31 to 2027-12-31 estimated range: [126.76$, 170.21$]
Financial Metrics affecting the NVS estimates:
- Negative: with PPE of 15.3 at the end of fiscal year the price was high
- Positive: 6.62 < Operating cash flow per share per price, % of 7.21
- Positive: Operating profit margin, % of 31.15 > 18.40
- Positive: Return on assets ratio (scaled to [-100,100]) of 10.83 > 6.02
- Positive: 5.50 < Industry operating cash flow per share per price (median), % of 5.61
- Positive: -4.39 < Investing cash flow per share per price, % of -1.84
- Positive: Inventory ratio change, % of 0.50 <= 0.80
Short-term NVS quotes
Long-term NVS plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $46,660.00MM | $51,722.00MM | $54,811.25MM |
| Operating Expenses | $36,891.00MM | $37,178.00MM | $37,737.26MM |
| Operating Income | $9,769.00MM | $14,544.00MM | $17,073.99MM |
| Non-Operating Income | $-646.00MM | $-904.00MM | $-638.25MM |
| Interest Expense | $876.12MM | $1,036.41MM | $1,187.05MM |
| R&D Expense | $11,371.00MM | $10,022.00MM | $10,741.73MM |
| Income(Loss) | $9,123.00MM | $13,640.00MM | $16,435.74MM |
| Taxes | $551.00MM | $1,701.00MM | $2,397.21MM |
| Net Income(Loss)* | $14,850.00MM | $11,941.00MM | $14,055.61MM |
| Stockholders Equity | $46,667.00MM | $44,046.00MM | $46,130.08MM |
| Inventory | $5,913.00MM | $5,723.00MM | $6,269.01MM |
| Assets | $99,945.00MM | $102,246.00MM | $115,569.20MM |
| Operating Cash Flow | $14,458.00MM | $17,619.00MM | $19,242.03MM |
| Capital expenditure | $2,753.00MM | $3,814.00MM | $1,555.93MM |
| Investing Cash Flow | $5,596.00MM | $-7,513.00MM | $-4,901.98MM |
| Financing Cash Flow | $-14,278.00MM | $-11,742.00MM | $-14,943.13MM |
| Earnings Per Share** | $7.15 | $5.92 | $7.25 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.